Biopharma firm DBV Technologies SA's DBVT submission of BLA (biologics license application to the US FDA) for its VIASKIN ...

Châtillon, France, March 24, 2026DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual ReviewChanges went into ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...

DBV Technologies (DBVT) trades at a ~$1B market cap, but Viaskin faces a shrinking peanut allergy market and formidable ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document ...

DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced plans to initiate a new, pivotal Phase 3 clinical ...

Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...

Châtillon, France, March 26, 2026DBV Technologies Reports Full Year 2025 Financial Results and Business UpdateContinued advancing the VIASKIN® ...

On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American ...